Saey Sofie1, Piette Yves2, Verstraete Barbara3, Lambert Margareta4, Van Hoeyweghen Raf4, Vandekerckhove Bruno3, Haspeslagh Marc5, Grootaert Veerle1. 1. Department of Pharmacy, AZ Sint Jan Brugge-Oostende AV, Bruges, Belgium. 2. Department of Rheumatology, AZ Sint Jan Brugge-Oostende AV, Bruges, Belgium. 3. Department of Orthopedic Surgery, AZ Sint Jan Brugge-Oostende AV, Bruges, Belgium. 4. Department of Geriatrics, AZ Sint Jan Brugge-Oostende AV, Bruges, Belgium. 5. AZ Sint Jan Brugge-Oostende AV, Bruges, Belgium.
Abstract
OBJECTIVE: Osteoporosis is a common disease that is underdiagnosed and undertreated. A multidisciplinary intervention may improve the identification and treatment of osteoporosis and may consequently prevent secondary fractures. METHOD: Retrospective, single-centre study comparing attitude to screening and treatment of patients admitted to the orthopaedic unit of the general hospital AZ Sint-Jan Brugge-Oostende AV (Belgium) before and after the implementation of a clinical pathway. RESULTS: A total of 172 patients (86 before and 86 after) were included in this study. The implementation of the pathway resulted in an increase in bone mineral density tests performed, an increment in the number of referrals to a specialist in the field of osteoporosis, and an increase in prevention and treatment of osteoporosis. CONCLUSION: The implementation of a clinical pathway coordinated and evaluated by a clinical pharmacist improved the identification, referral and treatment of osteoporosis in patients hospitalised due to low-impact fractures.
OBJECTIVE: Osteoporosis is a common disease that is underdiagnosed and undertreated. A multidisciplinary intervention may improve the identification and treatment of osteoporosis and may consequently prevent secondary fractures. METHOD: Retrospective, single-centre study comparing attitude to screening and treatment of patients admitted to the orthopaedic unit of the general hospital AZ Sint-Jan Brugge-Oostende AV (Belgium) before and after the implementation of a clinical pathway. RESULTS: A total of 172 patients (86 before and 86 after) were included in this study. The implementation of the pathway resulted in an increase in bone mineral density tests performed, an increment in the number of referrals to a specialist in the field of osteoporosis, and an increase in prevention and treatment of osteoporosis. CONCLUSION: The implementation of a clinical pathway coordinated and evaluated by a clinical pharmacist improved the identification, referral and treatment of osteoporosis in patients hospitalised due to low-impact fractures.
Authors: S Boonen; H A Bischoff-Ferrari; C Cooper; P Lips; O Ljunggren; P J Meunier; J-Y Reginster Journal: Calcif Tissue Int Date: 2006-04-21 Impact factor: 4.333
Authors: L Bessette; S Jean; M-P Lapointe-Garant; E L Belzile; K S Davison; L G Ste-Marie; J P Brown Journal: Osteoporos Int Date: 2011-09-17 Impact factor: 4.507
Authors: J-J Body; P Bergmann; S Boonen; Y Boutsen; J-P Devogelaer; S Goemaere; J-M Kaufman; S Rozenberg; J-Y Reginster Journal: Osteoporos Int Date: 2010-05-18 Impact factor: 4.507
Authors: S B Jaglal; O S Donescu; V Bansod; J Laprade; K Thorpe; G Hawker; S R Majumdar; L Meadows; S M Cadarette; A Papaioannou; M Kloseck; D Beaton; E Bogoch; M Zwarenstein Journal: Osteoporos Int Date: 2011-07-16 Impact factor: 4.507